SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending as investors weigh significant operational shifts, including a major dividend reduction and the withdrawal of financial guidance, alongside a high-stakes earnings release. The community is actively debating the company's turnaround potential under new management, with intense speculation from retail traders regarding a possible short squeeze fueled by significant institutional ownership and high short interest.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending following a record-breaking earnings report that highlighted significant revenue growth and margin improvements, fueling intense community excitement around the company's scalable manufacturing and expanding pipeline. Investors are actively discussing the stock's substantial short interest and potential for a squeeze, while closely watching for upcoming clinical data catalysts in the lung cancer space.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is trending as investors focus on its pivot into AI infrastructure through the Quake AI acquisition and Northern Data integration, which has fueled speculation about potential government and cloud contracts. The community is heavily focused on a potential short squeeze given the high short interest, with many retail investors debating the long-term transformation of the company from a video platform into an AI compute powerhouse.

Doximity, Inc. engages in the development and operation of an online platform for medical professionals. Its cloud-based software has the ability to enable users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. The company was founded by Shari Buck, Konstantin Guericke, Nate Gross, and Jeffrey A. Tangney on April 16, 2010 and is headquartered in San Francisco, CA.

Doximity Inc - Ordinary Shares - Class A

Doximity Inc

Doximity is experiencing extreme volatility and a massive short squeeze driven by investor enthusiasm over the company's clinical AI developments and management's optimistic outlook. Community sentiment is deeply polarized, with many retail traders chasing the parabolic move as a 'pump' while others warn of a severe 'rug pull' given that the rally follows mixed earnings results.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is trending as investors weigh its role as a critical optical infrastructure provider against a broader sector sell-off and speculation surrounding potential U.S. restrictions on Chinese optical components. While the community actively debates whether the stock's recent volatility represents a healthy valuation reset or a breakdown in momentum, sentiment remains largely focused on the company's long-term supply agreements and its key position in the AI networking buildout.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing intense community debate following the recent Goliath layer-1 rollout and ongoing staking updates, with some investors betting on long-term institutional adoption while others express frustration over stagnant price action and lack of confirmed commercial partnerships. The conversation is currently dominated by conflicting views, ranging from bullish sentiment over its potential to become a financial infrastructure leader to sharp skepticism regarding the project's transparency and historical market performance.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is currently a focal point for investors as persistent insider accumulation, including significant open-market buys from the CEO and key directors, signals strong leadership conviction despite the stock's year-to-date decline. The community is actively debating whether the recent technical reversal and insider buying indicate a structural bottom or if the stock faces further downside risk ahead of its upcoming earnings report.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing heightened market attention ahead of upcoming quarterly earnings as investors monitor its progress in government-backed quantum sensing and computing projects. Community sentiment is largely bullish, with active discussions focusing on recent institutional accumulation, the company's competitive position in the quantum sector, and potential upside from strategic defense contracts.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as investors weigh strong recent quarterly earnings and a raised revenue outlook against ongoing concerns regarding the company's long-term growth and patent cliff. While some in the community highlight the stock's high dividend yield and potential for value-driven momentum, others express persistent frustration over the stock's historical range-bound price action and lackluster market performance.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera Biologics is currently in the spotlight as investors anticipate top-line Phase 2 data for its ABCL635 treatment for menopause-related symptoms, a critical readout expected to validate the company's proprietary discovery platform. While the stock has seen high volatility, community discussion is intensely focused on whether these upcoming results will demonstrate the efficacy needed to compete with established therapies and trigger a long-term re-rating of the company's valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

iShares Trust - iShares CMBS ETF

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

CMBSiShares CMBS ETF

Fundamentals

Connect Stocktwits to ChatGPT

Latest CMBS News